46 results about "MLH1" patented technology

Variant human MLH1 and MSH2 genes are provided. Methods of using these variant genes to diagnose hereditary non-polyposis colorectal cancer (HNPCC) and/or determine a patient's susceptibility to developing HNPCC are also provided. Methods and compositions for identifying new variant MLH1 of MSH2 genes are also provided. In addition, experimental models for hereditary non-polyposis colorectal cancer comprising these variant genes are provided.

The present invention is based, at least in part, on the generation of an animal model of pancreatic adenocarcinoma which recapitulates the genetic and histological features of human pancreatic adenocarcinoma, including the initiation, maintenance, and progression of the disease. Accordingly, the present invention provides animal models of cancer, e.g., pancreatic adenocarcinoma, wherein an activating mutation of Kras has been introduced, and any one or more known or unknown tumor suppressor genes or loci, e.g., Ink4a/Arf, Ink4a, Arf, p53, Smad4/Dpc, Lkb1, Brca2, or Mlh1, have been misexpressed, e.g., have been misexpressed leading to decreased expression or non-expression. The animal models of the invention may be used, for example, to identify biomarkers of pancreatic cancer, to identify agents for the treatment or prevention of pancreatic cancer, and to evaluate the effectiveness of potential therapeutic agents.

The invention relates to the field of meiotic homologous recombination in plants. Provided are transgenic plants, cytological assays and MLH1 protein and nucleic acid sequences, as well anti-MLH1 antibodies, anti-SMC1, anti-SMC3 and anti-CENP-C antibodies.

The invention relates to tumor susceptibility 62 genes and application thereof. The tumor susceptibility 62 genes comprise PTEN, STK11, CDH1, TP53, BRCA1, BRCA2, PALB2, CHEK2, ATM, BRIP1, NBN, RAD51C, MLH1, MSH2, MSH6, PMS2, BARD1, RAD51D, MRE11A, MUTYH, PMS1, RAD50, XRCC2, AKT1, PIK3CA, FANCC, RECQL, CCND1, ERBB2, ESR1, GATA3, FGFR1, MAP2K4, MAP3K1, BAI3, CTNNB1, BRAF, KRAS, CTNNA1, EPCAM, APC, BLM, SMAD4, BMPR1A, POLD1, POLE, AXIN2, MEN1, KIT, EGFR, EZH2, PRF1, CDKN2A, CDK4, BAP1, RB1, ERCC2, VHL, MET, FH, FLCN and RET. The detection of the genes can be used for evaluating tumor susceptibility.

The invention relates to a mismatch repair gene MLH1 mutation detection kit and application thereof. The kit comprises the main components: firstly, 20 pairs of MLH1 gene PCR (Polymerase Chain Reaction) amplification and sequencing primers; and secondly, a reagent for PCR amplification. A PCR amplification product obtained through the kit can be used for screening gene micromutation through a high resolution dissolution curve method or carrying out restriction fragment length polymorphism analysis. The kit has high efficient MLH1 gene mutation detection and function evaluation actions and is used for mismatch repair gene MLH1 mutation detection.

Type 1 diabetes (T1D) patients make antibodies to self-proteins that are potential biomarkers for early detection and risk prediction. We have identified seventeen antigens as biomarkers for early diagnosis and risk prediction of T1D, including the antigens MLH1, MTIF3, PPIL2, NUP50, TOX4, FIGN, C9orf142, ZNF280D, HES1, QRFPR, CTRC, SNX6, SYTL4, ELA2A, IGRP, PAX6, and HMGN3.

The invention relates to a kit for predicting colorectal cancer liver metastases and a use method. The kit includes a DNA database building kit, the DNA database building kit comprises probes of a plurality of genes, and the plurality of genes include: high risk genes: KRAS, BRAF, MLH1, NRAS, MSH2, PMS2, UGT1A1, MSH6 AKT1, PIK3CA, PTEN, SMAD4, TP53, NM23, TIAM1, MTS1; and low risk genes: PRKDC, RAD50, STAG2, XRCC5, XRCC6, FANCA, ATR, MUTYH, EMSY, ERCC4, RAD51, PARP1, XRCC1. The kit provided by the invention performs related mutation detection on colorectal cancer liver metastases related genes in peripheral blood, and combines specific scoring mechanism to rapidly and conveniently judge and predict colorectal cancer liver metastases.

The present invention provides a method and single-tube assay for identification and quantitative analysis of differentially methylated MLH1 promoter sequences that are associated with certain types of cancer in an individual by obtaining a biological sample comprising DNA from the individual, detecting the presence of and measuring the level of methylated MLH1 promoter sequences, and comparing the presence of and level of methylation in the sample to a normalization reference of “normal” beta-actin gene promoters, wherein a difference in the level or pattern of MLH1 methylation of the sample compared to the Actin gene reference level identifies abnormally methylated MLH1 promoter sequences associated with cancer.

The present invention discloses an application of a MLH1 gene, and a kit for detecting a gastrointestinal stromal tumor, wherein the kit comprises MLH1 gene sequencing primers. According to the present invention, the inventor finds that: the gastrointestinal stromal tumor is caused by the common KIT and PDGFRA gene mutations, and the MLH1 (V384D) mutation is one of the causes of the gastrointestinal stromal tumor, such that the kit for detecting the gastrointestinal stromal tumor can be provided for rapidly and accurately detecting the MLH1 mutation site of the gastrointestinal stromal tumor and assistedly diagnosing the gastrointestinal stromal tumor so as to assistedly treat the gastrointestinal stromal tumor based on the finding; and after the MLH1 (V384D) mutation is detected by using the kit, the gene targeting drug can be adopted to specifically treat patients, such that the use of the targeting drug is specific.

The invention relates to a method for constructing an MLH1 gene knockout cell line, and relates to the technical field of gene engineering. According to the method, a CRISPR/Cas9 system is used to prepare an MLH1 gene knockout cell line, firstly designing two sgRNA sequences for the MLH1 gene, and constructing recombinant plasmids by utilizing molecular cloning technology; then transfecting the recombinant plasmids to HeLa cells, verifying the activity of sgRNA through PCR, carrying out puromycin drug screening and monoclonal treatment, extracting genome DNA and total protein of the monoclonalcell strain, and carrying out MSH1 gene level sequencing identification and expression detection of protein level to obtain an MSH1 gene knockout HeLa cell line. The MSH1 gene knockout HeLa cell lineconstructed by the invention is a cell line with stable inheritance of genes. The method provided by the invention can be used for directional knockout of the MSH1 gene to cause functional inactivation of the MSH1 gene, which has the characteristics of simplicity, convenience, high efficiency, quickness, low cost and the like, and has important significance for research on functions and related pathways of the MSH1 gene.

The present invention belongs to the field of biotechnology, and in particular relates to a kit, a method and primers for analyzing methylation status of an MLH1 promoter in a DNA sample. The invention provides a kit for analyzing the methylation status of a neoplastic disease associated MLH1 promoter in a DNA sample. The kit comprises oligonucleotide primers, the oligonucleotide primers are complementary with at least part of the sequence of the MLH1 promoter in a zone from -248bp to -178bp relative to a transcription start site and overlap with the methylation sites in the zone. The present invention discloses accurate and sensitive test, composition and method for detection of differential methylation of genomic MLH1 promoter DNA in clinical sample. The test, composition and method can be used in allow diagnosis and symptom method; and the applicable characteristic is that the presenting level of methylation genomic MLH1 promoter DNA in the absence of a specific disorder is distinguished from illness of methylation genomic MLH1 promoter DNA level.

The invention discloses a DNA methylation kit for colorectal cancer detection and a detection method thereof. The kit comprises a specific primer and a probe which are used for detecting or measuringa methylation state or level of one or more specific genes in DNA of a tested sample, wherein the specific genes are SEPT9, MLH1 and ACTB. The kit provided by the invention can significantly improve the positive detection rate and specificity (real negative rate) of early colorectal cancer; the detection sensitivity of a biomarker can be improved to a pg/nanogram-grade DNA molecule, and the improvement of the detection sensitivity is realized by optimizing a specific nucleotide sequence primer and a DNA probe and improving a bisulfite treatment method of plasma free DNA.

Therapeutic approaches to the treatment of DNA mismatch repair (MMR) deficient cancers are disclosed based on the use of complimentary gene-function and drug screening synthetic lethality approaches for designing therapies for the treatment of cancers where loss of tumour suppressor function has occurred. The work is based on experiments using human MSH2, an integral component of the MMR pathway, and is applicable to other genes in the MMR pathway, and in particular MLH1, MSH6, PMS1 and PMS2. In particular loss of MSH2 is synthetically lethal with inhibition of the DNA polymerase POLβ deficiency of MLH1 is synthetically lethal with DNA polymerase γ (POLG) inhibition.

The invention belongs to the field of molecular biology and medicine, and particularly relates to a DNA mismatch repair gene (MMR) mutation detection kit and uses thereof, more particularly to mutation detection of human MLH1 gene, human MSH2 gene, human MSH6 gene, human PMS1 gene and human PMS2 gene, and detection of the correlation with hereditary nonpolyposis colorectal cancer (HNPCC). According to the present invention, the kit can be used for detecting the genotype of the exon mutation of the individual MMR gene so as to provide the reference data for judging whether the individual has HNPCC and whether the suffering risk of family members is greater than the suffering risk of the general populations.

The invention discloses a kit for homologous recombination repair defect detection. A multi-probe targeted capture technology is combined with a next-generation sequencing technology to enrich and detect the variation conditions of 25 genes, wherein the 25 genes include ARID1A, BRCA1, BRCA2, POLG, ATR, BRIP1, MSH2, RAD51C, ATM, MLH1, MRE11A, RAD50, ATRX, CHECK1, MUTYH, RAD51D, BAP1, CHECK2, NBN, SMARCB1, BARD1, FANCE, PALB2, WRN and BLM.

The invention discloses a mutant gene group, library and kit for evaluating female malignant tumor risk, and belongs to the technical field of biomedical molecular detection. The mutant gene group forevaluating the risk of female malignant tumors comprises one or more selected from a group consisting of the following 25 genes: ATM, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, EPCAM, MLH1, MSH2, MSH6, NBN, NF1, PALB2, PMS2, PTEN, RAD51C, RAD51D, STK11, TP53, BARD1, MRE11A, MUTYH, RAD50, XRCC2 and FANCC5. According to the invention, female malignant tumor related genetic markers can be widely screened andinspected, accuracy is higher, and a basis is provided for prediction, prevention and diagnosis of female malignant tumor onset risks.

The invention discloses C-terminal specific human DNA mismatch repair protein MLH1 polypeptide, as well as an antibody and a preparation method thereof, belonging to the biomedicine technical field. The amino acid sequence of the C-terminal specific human MLH1 polypeptide is SLEGDTTKGTSEMSE. Antihuman MLH1 polypeptide antibody is prepared according to the following method that: (1) human MLH1 epitope is analyzed; (2) human MLH1 C-terminal polypeptide is synthesized; (3) synthesized polypeptide is crosslinked with carrier protein; (4) rabbit anti-human MLH1 polypeptide antibody is prepared; (5) serum containing the antibody is obtained through collection and separation, and the antibody is purified, and then the antihuman MLH1 polypeptide antibody can be obtained. The C-terminal specific antihuman MLH1 synthesized polypeptide antibody is high in potency, strong in affinity, good in specificity, capable of having specific binding reaction with natural human DNA mismatch repair protein MLH1 and low in preparation cost; purified antibody can be completely used for immunoblot and enzyme linked immunosorbent assay, as well as the establishment of in vitro immunization analytical method. The antibody provides a useful tool for the research on human MLH1 biological function as well as the relation between the human MLH1 and related diseases.

The invention discloses a kit for detecting sensitivity of a tumor targeted drug. The kit comprises an optional reagent for detecting the expression level of MLH1. The invention also discloses application of the reagent to detection of the expression level of the MLH1 in preparation of the kit for detecting the sensitivity of the tumor targeted drug. The kit has the advantages that by detecting the expression level of the MLH1, the sensitivity of a tumor patient to the targeted drugs (sorafenib and sunitinib) can be judged, the drug treatment effect on the tumor patient can be predicted in theclinical application, the basis is provided for the patient to take the related treatment measure or decision, and the clinical application prospect is good.

A method for detecting an abnormal cell based on gene expression analysis, which is useful for cancer diagnosis, is provided. A gene expression analysis method, comprising: measuring the expression level of a transcript of a human MLH1 gene containing the nucleotide sequence as shown in SEQ ID NO: 1 at the 5′-terminus thereof and the expression level of a transcript of a human MLH1 gene containing the nucleotide sequence as shown in SEQ ID NO: 2 at the 5′-terminus thereof, in a biological sample; and comparing the expression levels, thereby detecting a cell positive for microsatellite instability.

The invention discloses a gene library constructing method for a hereditary gastrointestinal tumor, and relates to mutation of 7 genes, namely APC, CDH1, MSH2, MLH1, MSH6, PMS2 and EPCAM. Target regions are exon regions of encoding amino acids of the 7 genes and respective 20 base regions at the upstream and the downstream of exons. In order to ensure complete coverage of the target regions, a primer group necessary for PCR amplification is separated into two independent primer groups, and the target regions are amplified respectively. Then, sequencing tag connection, library elution and re-amplification are performed on a PCR product, and purification is performed after the amplification to obtain a sequencing library. The library constructing method is simple and rapid in steps, the costof library construction is effectively reduced and genes related to the gastrointestinal tumor are covered. Through combination with a high-throughput sequencing instrument, mutation of the related genes can be quickly and accurately obtained, so that the gene library constructing method is of great significance for the hereditary gastrointestinal tumor.

The invention discloses a kit for detecting human MLH1 gene methylation and a use method of the kit. The kit comprises a specific primer and a probe which are used for detecting or measuring the methylation state or level of the MLH1 gene in DNA of a tested sample. The kit can significantly increase the positive detection rate and specificity (real negative rate) of early colorectal cancer and canimprove the detection sensitivity of a biomarker to a picogram/nanogram level DNA molecule, and the improvement of the detection sensitivity is realized by optimizing a specific nucleotide sequence primer and a DNA probe and improving a bisulfite treatment method of plasma free DNA.